Development of endometrioid adenocarcinoma despite Levonorgestrel‐releasing intrauterine system: a case report with discussion and review of the <scp>RCOG</scp>/<scp>BSGE</scp> Guideline on the Management of Endometrial Hyperplasia

Meer, A. C. L. van der; Hanna, Louise

doi:10.1111/cob.12168

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Согласно большинству международных исследований, при М-ЭХО менее 7-8 мм в репродуктивном возрасте, а также менее 3-4 мм в постменопаузе вероятность выявления ГЭ и РЭ составляет менее 1% [29,30]. Соответственно, выявление М-ЭХО больше указанных значений требует проведения тщательного диагностического поиска в отношении предраковой и онкопатологии [26,28,31,32].…”

Section: узи органов малого тазаunclassified

Traits of intrauterine pathology management in the peri- and postmenopausal period

Ivanov,

Dumanovskaya

2024

Medicinskij sovet

View full text Add to dashboard Cite

Increasing number of anovulatory cycles in the perimenopause, leading to relative hyperestrogenism, and persistent hypoestrogenism in postmenopause, increase the proliferative activity and change the endometrium morphology. That is associated with higher rates of intrauterine pathology. The prevalence of atypical hyperplasia and endometrial cancer in women of the peri- and postmenopausal periods reaches its maximum values. Therefore, one of the most important concepts of patient’s management is to exclude malignant and precancerous endometrial pathology. Significant hormonal changes leads to important confounders in diagnostic and therapeutic algorithms. It could lead to both hypo- and hyperdiagnosis. The review analyzes the main causes of abnormal uterine bleeding, the features of their clinical manifestation, taking into account probable iatrogenic causes, extrauterus and extragenital sources of spotting. This article reviews the principles of ultrasound examination, considering menstrual cycle phase, duration of menopause, hormone treatment, as well as indications for endometrial biopsy, in case of inconsistency of clinical presentation, ultrasound results, menopausal status and iatrogenic factors. We describe the relevant principles of medical correction, wait-and-see tactics and surgical treatment of abnormal uterine bleeding, both in the presence of organic pathology of the endometrium, and in its absence.

show abstract

Section: узи органов малого тазаunclassified

Traits of intrauterine pathology management in the peri- and postmenopausal period

Ivanov,

Dumanovskaya

2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Age, obesity, anovulatory cycles-PCOs, perimenopause, null parity, diabetes mellitus and ovarian tumors-granulosa cell tumors are some of the risk factors for endometrial hyperplasia [48,49]. It can also be caused by immune suppression (in renal graft recipients) and infection [50][51][52] Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, puts women at a higher risk of endometrial hyperplasia [53,54].…”

Section: Risk Factors For Endometrial Cancermentioning

confidence: 99%

A review on nanoparticles targeting cervical and endometrial cancer

Pepakayala¹,

Nalli²,

Ravi³

et al. 2022

World J. Bio. Pharm. Health Sci.

View full text Add to dashboard Cite

The two most frequent gynecological cancers in women globally are cervical and endometrial cancers. Despite the fact that a variety of medications have been created for treatment, they frequently result in a number of negative side effects, toxicity, and multidrug resistance (MDR). Despite the fact that surgery and chemo radiotherapy can cure 80–95 percent of women with early-stage cancer, recurring and metastatic disease remains a leading cause of cancer death. To address this, scientists have taken advantage of the benefits afforded by nano systems, such as nanocarriers in the fields of tumor targeting, increased drug accumulation in tumors, and so on. The major characteristics of this system include biodegradability, biocompatibility, non-toxicity, prolonged circulation, and a large payload range of a therapeutic drug. Anticancer treatment side effects can be decreased by encapsulating the drug and delivering it directly to the cancer site. Drug release at cancer locations using stimuli responsive nanocarriers is effective for achieving target-specific delivery. When compared to the conventional system, these methods exhibit improved ability to target malignant cells without harming healthy cells and offer the promise for advanced cancer therapy. Recent breakthroughs in intrinsic and extrinsic-stimulus sensitive nanomaterial systems for drug administration in cancer therapy, as well as other polymeric nano particles employed in cancer therapy, are discussed in this study.

show abstract

Endometrial Hyperplasia: Diagnosis and Management

Patel

2019

Preventive Oncology for the Gynecologist

View full text Add to dashboard Cite

Development of endometrioid adenocarcinoma despite Levonorgestrel‐releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia

Cited by 8 publications

References 20 publications

Traits of intrauterine pathology management in the peri- and postmenopausal period

Traits of intrauterine pathology management in the peri- and postmenopausal period

A review on nanoparticles targeting cervical and endometrial cancer

Endometrial Hyperplasia: Diagnosis and Management

Contact Info

Product

Resources

About